Analysts were bullish on Netflix stock ahead of its earnings beat, but what is Wall Street saying now? We take a closer look.
BTIG lowered the firm’s price target on Evolent Health (EVH) to $20 from $29 but keeps a Buy rating on the shares. The firm notes it was ...
Barclays lowered the firm’s price target on Visteon (VC) to $115 from $140 and keeps an Overweight rating on the shares as part of a Q4 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback